#USA #Washington #financial results #Danaher Corporation #Q2 2026

Danaher Corporation Reports Second Quarter 2026 Results

On July 21, 2026, Danaher Corporation (NYSE: DHR) released its financial results for the second quarter of 2026, revealing notable achievements in earnings and revenues that highlight the company's operational strength and strategic initiatives. The results signify a successful continuation of the organization's commitment to innovation and improvement across its core business areas.

Key Financial Highlights

Danaher reported a net earnings figure of $870 million, equating to $1.23 per diluted common share. This marks a remarkable 60% increase compared to the same period last year. Additionally, the non-GAAP adjusted diluted net earnings per common share saw a substantial rise of 8.0%, reaching $1.94. Revenues for the quarter climbed to $6.3 billion, translating to a 5.5% growth from the previous year, with non-GAAP core revenue increasing by 3.0% year-over-year. This robust performance is largely attributed to the accelerated growth in the life sciences and diagnostics segments, reflecting a strong market recovery and improved operational efficiencies.

The company generated an operating cash flow of $1.5 billion, and its non-GAAP free cash flow was $1.3 billion, signaling a strong cash position that allows for reinvestment and growth initiatives. Notably, the successful completion of the Masimo acquisition ahead of schedule underpins the evident growth trajectory and the company’s ability to enhance its operational capabilities.

Rainer M. Blair, the President and CEO of Danaher, commented on the second quarter's performance, stating, "We delivered a better than expected second quarter, with core growth improving versus the first quarter and disciplined execution driving high-single-digits adjusted EPS growth. Our Life Sciences businesses delivered their strongest quarter in several years and while customer project timing impacted bioprocessing revenue, underlying order trends remained strong and bioprocessing orders grew mid-teens in the quarter."

Looking Ahead

As Danaher moves forward, the company forecasts a continued end-market recovery driven by traction from its recent growth initiatives. Management anticipates exiting 2026 with a mid-single-digit core revenue growth rate. This outlook reinforces Danaher’s commitment to harnessing its cutting-edge portfolio, capital deployment options, and a skilled team, all supported by the Danaher Business System.

For the third quarter of 2026, Danaher expects non-GAAP core revenue to increase between 2.0% and 3.0% year-over-year. The full year forecast for non-GAAP core revenue is estimated to rise by 3.0% to 4.0%. Furthermore, the company has also raised its adjusted diluted net earnings per common share guidance for the full year to a range of $8.45 to $8.60 from the previous $8.35 to $8.55.

Conference Call Details

Danaher will hold an investor conference call on the same day to discuss the quarterly results and the outlook for the third quarter and full year of 2026. Interested parties can access the call through the Investors section of Danaher's website, along with an accompanying slide presentation. A replay will be available after the live session.

About Danaher

Danaher Corporation is a leading innovator in life sciences and diagnostics, devoted to leveraging the power of science and technology to enhance human health. The company boasts a vast ecosystem of industry-leading businesses that collaborate with customers to tackle scientific and clinical hurdles, facilitating faster movement from discovery to delivery for innovations essential to patient care. Driven by the Danaher Business System, the corporation emphasizes operational excellence, continuous improvement, and ultimately aims to create sustainable long-term value for shareholders while improving global health outcomes. For more information, visit www.danaher.com.